Table 1.

Baseline characteristics of intention-to-treat participants

VariableControl, n=266AST-120, n=272P Value
Age, yr56.8±13.256.7±13.30.93
Sex, women/men (%)88/178 (33.1/66.9)87/185 (32.0/68.0)0.79
ESRD cause, n (%)>0.99
 Diabetic133 (50.0)136 (50.0)
 Nondiabetic133 (50.0)136 (50.0)
BMI, kg/m224.5±3.524.7±3.90.97
BSA, m21.73±0.181.73±0.170.97
SBP, mmHg129.5±15.81129.2±14.70.65
DBP, mmHg75.8±10.275.8±9.90.85
Serum Cr, mg/dl2.84±0.702.82±0.660.79
eGFR, ml/min per 1.73 m226.6±7.326.9±7.70.79
CKD stage 3/4, n (%)78/188 (29.3/70.7)72/200 (26.5/73.5)0.50
Urinary protein, g/g Cr1.30 (0.41, 2.91)1.18 (0.40, 2.89)0.46
Hb, g/dl11.3±1.711.4±1.90.67
Albumin, g/dl4.0±0.54.0±0.40.46
Uric acid, mg/dl8.1±1.78.3±2.10.30
LDL, mg/dl95.3±38.292.1±28.90.84
CRP, mg/dl0.12 (0.026, 0.49)0.12 (0.027, 0.42)0.40
Serum β2-MG, mg/L6.73 (4.98, 8.39)6.30 (4.89, 7.97)0.28
Serum IS, mg/dl0.53 (0.24, 0.93)0.50 (0.26, 0.82)0.87
Urine IS, mg/dl5.52 (3.01, 9.58)5.16 (2.94, 9.12)0.60
RAS inhibitor, n (%)238 (89.5)249 (91.5)0.46
β-Blocker, n (%)141 (53.0)144 (52.9)>0.99
Calcium channel blocker, n (%)180 (67.7)177 (65.1)0.58
Diuretics, n (%)154 (57.9)173 (63.6)0.19
Lipid modifier, n (%)179 (67.3)185 (68.0)0.92
  • Continuous variables: mean±SD or median (25%, 75%). BMI, body mass index; BSA, body surface area; SBP, systolic BP; DBP, diastolic BP; Cr, creatinine; Hb, hemoglobin; CRP, C-reactive protein; β2-MG, β2-microglobulin; IS, indoxyl sulfate; RAS, renin-angiotensin-aldosterone system.